Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy Journal Article


Authors: Yood, M. U.; McCarthy, B. D.; Kempf, J.; Kucera, G. P.; Wells, K.; Oliveria, S.; Stang, P.
Article Title: Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy
Abstract: Background: Studies indicate that, overall, African Americans are less likely to achieve control of hyperlipidemia compared with whites. No population-based studies have examined the effect of race on achieving target low-density lipoprotein (LDL) goals among treated individuals. Methods: Using computerized encounter and laboratory result data, we identified all African American and white patients in a Midwestern health system filling a statin prescription from January 1, 1997, through June 30, 2001 (index prescription), with no prescriptions filled 1 year before index prescription. We followed LDL results for 1 year after index prescription. Results: A total of 16 052 new statin users (32.5% African American) were identified. Mean baseline LDL was higher for African Americans (170.2 ± 36.6) than for whites (161.8 ± 37.2) (P < .001). Whites were more adherent to therapy, with 48.6% of white patients exposed to statins >80% of follow-up time (31.2% of African Americans) (P < .001). By the end of follow-up, 49.5% of African Americans and 71.1% of whites reached LDL goal. A proportional hazards model adjusting for age, sex, median household income, physician specialty, clinic site, baseline LDL, starting dose, and target LDL indicated that African Americans were less likely to reach goal compared with whites (hazard ratio 0.64, 95% CI 0.61-0.68). Results persisted after controlling for racial differences in statin adherence and LDL testing (hazard ratio 0.60, 95% CI 0.57-0.63). Conclusions: African American patients initiating statin therapy are less likely to achieve LDL goal, even after controlling for adherence differences and other factors, suggesting that African Americans may require different pharmacologic management. © 2006 Mosby, Inc. All rights reserved.
Keywords: adult; controlled study; treatment outcome; aged; middle aged; retrospective studies; major clinical study; dose response; united states; comparative study; follow up; follow-up studies; cohort studies; proportional hazards models; age; confidence interval; health care; prescription; computer; laboratory; patient compliance; medical specialist; physician; time series analysis; race difference; african americans; european continental ancestry group; atorvastatin; hydroxymethylglutaryl coenzyme a reductase inhibitor; simvastatin; hyperlipidemia; african american; income; caucasian; goals; hyperlipidemias; sex; fluindostatin; medical records; hydroxymethylglutaryl-coa reductase inhibitors; mevinolin; pravastatin; low density lipoprotein; lipoproteins, ldl; hazard assessment
Journal Title: American Heart Journal
Volume: 152
Issue: 4
ISSN: 0002-8703
Publisher: Mosby, Inc  
Date Published: 2006-10-01
Start Page: 777
End Page: 784
Language: English
DOI: 10.1016/j.ahj.2006.02.036
PUBMED: 16996858
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 4 June 2012" - "CODEN: AHJOA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors